Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Equities research analysts at Leerink Partnrs dropped their Q4 2025 earnings per share estimates for Exact Sciences in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.14 per share for the quarter, down from their prior forecast of $0.22. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.87) per share.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year.
Check Out Our Latest Stock Report on EXAS
Exact Sciences Trading Down 23.5 %
NASDAQ:EXAS opened at $54.72 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. Exact Sciences has a one year low of $40.62 and a one year high of $79.62. The business’s 50-day simple moving average is $67.14 and its 200 day simple moving average is $56.65. The stock has a market cap of $10.11 billion, a price-to-earnings ratio of -57.00 and a beta of 1.27.
Insider Activity
In other news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.36% of the company’s stock.
Hedge Funds Weigh In On Exact Sciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAS. Private Advisor Group LLC grew its holdings in Exact Sciences by 12.5% in the 1st quarter. Private Advisor Group LLC now owns 26,974 shares of the medical research company’s stock worth $1,863,000 after buying an additional 2,999 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in Exact Sciences by 1.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock worth $825,000 after buying an additional 200 shares in the last quarter. Motive Wealth Advisors bought a new position in Exact Sciences in the 1st quarter worth approximately $201,000. Oppenheimer & Co. Inc. grew its holdings in Exact Sciences by 1.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,088 shares of the medical research company’s stock worth $1,594,000 after buying an additional 401 shares in the last quarter. Finally, ClariVest Asset Management LLC grew its holdings in Exact Sciences by 32.4% in the 1st quarter. ClariVest Asset Management LLC now owns 25,313 shares of the medical research company’s stock worth $1,748,000 after buying an additional 6,192 shares in the last quarter. 88.82% of the stock is owned by institutional investors.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
- Five stocks we like better than Exact Sciences
- Which Wall Street Analysts are the Most Accurate?
- Fiserv Is Up 50% This Year and Can Go Another 50% Higher
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Monster Beverage Is a Scary Good Deal at Current Levels
- How to Calculate Return on Investment (ROI)
- 2 Online Educational Platforms Staging a Turnaround
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.